Trial Profile
A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Laquinimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Biomarker
- Sponsors Teva Pharmaceutical Industries
- 03 May 2014 Pharmacokinetic results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 29 Apr 2014 Status changed from recruiting to completed.